Tagraxofusp: Safety and Efficacy of Combing TAG with AZA and AZA+VEN
Safety and Efficacy of Combining Tagraxofusp with AZA or AZA+VEN in a Phase 1b…
EMERALD: Phase 3 Results in ER+/HER2- advanced/metastatic breast cancer (mBC)
Elacestrant, an oral selective estrogen receptor degrader (SERD), vs…
Tagraxofusp: A Multicenter Phase 1/2 Trial in Patients with Poor-Risk MF
A Multicenter Phase 1/2 Trial of Tagraxofusp in Patients with Poor-Risk MF. ASH…
Phase 1: Final Analysis of ELACESTRANT in ER+/HER2- Advanced Breast Cancer
Final analysis of phase 1 study of elacestrant (RAD1901), a novel selective…
Tagraxofusp Alone and in Combination with Ruxolitinib for Treatment of Myeloproliferative Neoplasms
Evaluation of Tagraxofusp(SL-401) Alone and in Combination with Ruxolitinib for…
Results from Clinical Trial of Tagraxofusp in Patients with Intermediate or High Risk R/R MF
Results from Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with…
Tagraxofusp in Combination with POM/DEX in Relapsed or Refractory Multiple Myeloma
Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide…
CD123+ plasmacytoid dendritic cells (pDCs) from SSc patients are susceptible to tagraxofusp
CD123+ plasmacytoid dendritic cells (pDCs) from SSc patients are susceptible to…
Outcomes of Tagraxofusp (SL-401) in Older Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Outcomes of Tagraxofusp (SL-401) in Older Patients with Blastic Plasmacytoid…
Interim Results from a Phase 1 Trial of SL-801, a Novel XPO1 Inhibitor, in Patients with Advanced Solid Tumors
Interim Results from a Phase 1 Trial of SL-801, a Novel XPO1 Inhibitor, in…